Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas H. Althuis is active.

Publication


Featured researches published by Thomas H. Althuis.


The Journal of Clinical Pharmacology | 1981

Selective and potent analgetics derived from cannabinoids.

Michael Ross Johnson; Lawrence S. Melvin; Thomas H. Althuis; J. S. Bindra; Charles Armon Harbert; George Mclean Milne; Albert Weissman

Abstract: Based on the hypothesis that analgetic activity is a dissociable feature of the cannabinoid molecule, we examined modifications of the side chain, the phenolic moiety, and, most significantly, structures that lack the benzopyran functionality present in THC and (—)‐9‐nor‐9β‐hydroxyhexahydrocannabinol (HHC). A new grouping, the 1‐methyl‐4‐phenylbutyloxy C‐3 side chain, elaborates a unique lipopholic region. Replacement of the phenol substituent produced several derivatives which retain analgetic activity in the codeine potency range. Introduction of a weakly basic nitrogen at C‐5 and deletion of the axial methyl group in the B ring, two structural changes forbidden by traditional cannabinoid SAR, resulted in a unique family of benzoquinolines with potent analgetic activity. The prototype of this series, levonantradol, exhibits potent and stereospecific analgetic and antiemetic activity.


Drug Information Journal | 1992

A Therapeutic and Economic Comparison of the Top Innovative New Drugs of the 1970s and 1980s

Thomas H. Althuis

The economically most important drugs introduced in the US in the 1980s represented distinct therapeutic advances over those of the 1970s. However, most recently, the strong post- World War II technological leadership of US based companies is clearly being challenged. Of the top 36 new chemical entities (NCEs) approved and marketed in the US in the 1980s, US based companies received a significantly smaller market share than they did for those NCEs approved in the 1970s, while during the same period, foreign based companies more than doubled their share of NCEs in this critical portion of the US market. Furthermore, discoveries of top drugs by US based companies decreased even more markedly from the 1970s to the 1980s. US based companies were able to continue to maintain their dominance in the upper end of the US market in the 1980s only by licensing more drugs from foreign sources. A cohesive set of national policies is needed to assure strong US leadership through the 1990s.


Archive | 1979

1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor

Thomas H. Althuis; Charles Armon Harbert; Michael Ross Johnson; Lawrence S. Melvin


Archive | 1977

3-[2-Hydroxy-4-(substituted)-phenyl]azacycloalkanes and derivatives thereof as analgesic agents and intermediates therefor

Thomas H. Althuis; Charles Armon Harbert; Michael Ross Johnson; Lawrence S. Melvin


Archive | 1979

3-[2,4-(Disubstituted)-phenyl]azacycloalkanones as analgesics

Thomas H. Althuis; Charles Armon Harbert; Michael Ross Johnson; Lawrence S. Melvin


Archive | 1977

Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents

Thomas H. Althuis


Archive | 1977

Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives

Thomas H. Althuis; Charles Armon Harbert; Michael Ross Johnson; Lawrence S. Melvin


Archive | 1978

3- eckige klammer auf 2-hydroxy-4- (substituierte)-phenyl eckige klammer zu -azacycloalkane und derivate hiervon, sowie deren verwendung als analgetika

Thomas H. Althuis; Charles Armon Harbert; Michael Ross Johnson; Jun Lawrence Sherman Melvin


Archive | 1976

Fused pyrimidin-4(3H)-ones as antiallergy agents

Thomas H. Althuis; Leonard J. Czuba; Hans-Jurgen E. Hess; Saul B. Kadin


Archive | 1980

3-(2-Hydroxy-4-(substituted)phenyl)azacycloalkanes as analgesics

Thomas H. Althuis; Charles Armon Harbert; Michael Ross Johnson; Lawrence S. Melvin

Researchain Logo
Decentralizing Knowledge